New drug aims to unmask melanoma to the immune system
Disease control
Ongoing
This early-stage trial tests a new oral drug, SX-682, combined with the immunotherapy pembrolizumab in people with advanced melanoma. The goal is to see if SX-682 can stop cancer from hiding from the immune system, making the immunotherapy work better. About 77 participants will …
Phase: PHASE1 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC